Inhibition of cytochrome P450 2B6 by Astragalus extract mixture HT042

被引:0
|
作者
Harim Kim
Yejin Lee
Vitchan Kim
Rowoon Lee
Soo Kyung Bae
Mi-Kyoung Kwak
Sung Hoon Lee
Donghak Kim
机构
[1] Konkuk University,Department of Biological Sciences
[2] The Catholic University of Korea,College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences
[3] Chung-Ang University,College of Pharmacy
来源
Toxicological Research | 2020年 / 36卷
关键词
Cytochrome P450; P450 2B6; Astragalus; Shanzhiside methylester; UPLC–MS/MS;
D O I
暂无
中图分类号
学科分类号
摘要
Astragalus extract mixture (AEM) HT042 is a functional food approved by the MFDS (Korean FDA) for increasing height. It comprises a mixture of three standardized extracts from Astragalus membranaceus root, Eleutherococcus senticosus stem, and Phlomis umbrosa root. In this study, drug–functional food interaction was analyzed using six major human cytochrome P450 enzymes. The inhibitory effect of AEM HT042 on P450 activities was studied using a P450–NADPH P450 reductase reconstitution system. Among the six P450 enzymes (1A2, 2A6, 2B6, 2D6, 2C9, and 3A4), only P450 2B6 activity was markedly decreased by AEM HT042 addition. The bupropion hydroxylation activity of P450 2B6 was analyzed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC–MS/MS). A calculated IC50 value of 10.62 µg/ml was obtained. To identify the inhibitory compounds in the mixture, four active compounds in AEM HT042 were analyzed. Shanzhiside methylester exhibited inhibitory effects on P450 2B6, whereas formononetin, eleutheroside E, and sesamoside did not affect P450 2B6 activity at all. Our results suggest that shanzhiside methylester in AEM HT042 is responsible for the inhibitory effect on P450 2B6 metabolism. Characterization of the inhibitory effect on P450 can help determine the safe administration of functional foods along with many clinical drugs that are metabolized by P450.
引用
下载
收藏
页码:195 / 201
页数:6
相关论文
共 50 条
  • [41] Potent inhibition of cytochrome P450 (CYP) 2B6 catalyzed efavirenz 8-hydroxylation by ticlopidine and clopidogrel.
    Huh, W
    Jones, DR
    Desta, Z
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P78 - P78
  • [42] Halogen-π Interactions in the Cytochrome P450 Active Site: Structural Insights into Human P450 2B6 Substrate Selectivity.
    Shah, Manish B.
    Liu, Jingbao
    Zhang, Qinghai
    Stout, C. David
    Halpert, James R.
    FASEB JOURNAL, 2017, 31
  • [43] Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline
    Paulo Roberto Xavier Tomaz
    Mariana Soares Kajita
    Juliana Rocha Santos
    Jaqueline Scholz
    Tânia Ogawa Abe
    Patrícia Viviane Gaya
    José Eduardo Krieger
    Alexandre Costa Pereira
    Paulo Caleb Júnior Lima Santos
    European Journal of Clinical Pharmacology, 2019, 75 : 1541 - 1545
  • [44] Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline
    Xavier Tomaz, Paulo Roberto
    Kajita, Mariana Soares
    Santos, Juliana Rocha
    Scholz, Jaqueline
    Abe, Tania Ogawa
    Gaya, Patricia Viviane
    Krieger, Jose Eduardo
    Pereira, Alexandre Costa
    Junior Lima Santos, Paulo Caleb
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (11) : 1541 - 1545
  • [45] Inhibition of cytochrome P450 2A6 by phenylpropanoids
    Chan, Jeannine
    McArthur, Kandice
    Brennen, Kevin
    Harrelson, John
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [46] Dual Ligand Complexes of Human Cytochrome P450 2B6 and Rabbit Cytochrome P450 2B4 with Amlodipine Reveal Substrate Access Channels into the Active Site
    Shah, Manish B.
    Stout, C. David
    Halpert, James R.
    FASEB JOURNAL, 2012, 26
  • [47] Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate
    Mohamed, Mohamed-Eslam F.
    Minocha, Mukul
    Trueman, Sheryl
    Feng, Tian
    Enejosa, Jeffrey
    Fisniku, Ogert
    Othman, Ahmed A.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (03): : 299 - 306
  • [48] Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
    Farid, Nagy A.
    Payne, Christopher D.
    Ernest, Steven, II
    Li, Y. Grace
    Winters, Kenneth J.
    Salazar, Daniel E.
    Small, David S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (01): : 53 - 59
  • [49] Polymorphism of cytochrome P450 2B6 and prostate cancer risk: A significant association in a Japanese population
    Kurosaki, Takayuki
    Suzuki, Motofumi
    Enomoto, Yutaka
    Arai, Tomio
    Sawabe, Motoji
    Hosoi, Takayuki
    Homma, Yukio
    Kitamura, Tadaichi
    INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (04) : 364 - 368
  • [50] Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation
    Fan, Lan
    Wang, Jin-Chao
    Jiang, Feng
    Tan, Zhi-Rong
    Chen, Yao
    Li, Qing
    Zhang, Wei
    Wang, Guo
    Lei, He-Ping
    Hu, Dong-Li
    Wang, Dan
    Zhou, Hong-Hao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (04) : 403 - 409